Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's patent cliff the real test ahead?

With Keytruda driving most of Merck's revenue, can the company's oncology pipeline and new ventures offset looming patent losses? U.S. investors get exposure to a pharma leader in immunology and vaccines amid shifting industry dynamics. ISIN: US58933Y1055

You rely on pharma giants like Merck & Co., Inc. for breakthroughs in cancer treatment and vaccines, but as Keytruda's dominance faces a 2028 patent expiration, you're right to question if the stock's stability holds up. Merck generates over 40% of its sales from this blockbuster immunotherapy, making the transition to next-generation drugs a pivotal moment for shareholders. The company's diversified portfolio in vaccines and animal health offers some buffer, yet execution on pipeline candidates will determine if growth sustains for investors in the United States and English-speaking markets worldwide.

Updated: 14.04.2026

By Elena Vargas, Senior Pharma Equity Analyst – Merck's oncology leadership meets pipeline pressures in a high-stakes transition.

Merck's Core Business Model: Oncology at the Center

Merck & Co., Inc., trading as US58933Y1055 on the NYSE, builds its business around innovative pharmaceuticals, with a heavy emphasis on oncology, vaccines, and hospital medicines. You see Keytruda, or pembrolizumab, as the star performer, approved for multiple cancers including melanoma, lung, and head and neck types, generating tens of billions in annual revenue. This PD-1 inhibitor exemplifies Merck's strategy of partnering with innovators like Organon for development, then scaling global sales through a robust commercial network.

The model extends to vaccines like Gardasil for HPV prevention and animal health via Merck Animal Health, providing steady cash flows. For you as a U.S. investor, this structure means exposure to high-margin drugs protected by strong intellectual property, though reliance on a few blockbusters heightens vulnerability. Merck's focus on external innovation through licensing deals accelerates pipeline growth without the full R&D burden.

Hospital products such as Bridion for anesthesia reversal add defensive revenue, less cyclical than oncology. Overall, the model prioritizes high-unmet-need areas where Merck can command premium pricing, supporting dividends and buybacks that appeal to income-focused portfolios.

Key Products and Global Markets Driving Revenue

Keytruda leads with approvals in over 30 indications, targeting solid tumors via immunotherapy, making it essential for your portfolio's growth potential. Gardasil prevents cervical cancer, thriving in international markets where vaccination rates rise, while ProQuad and Vaxneuvance bolster the pediatric vaccine segment. You benefit from Merck's presence in emerging markets, where demand for affordable chronic disease treatments expands.

Animal health products like Nuflor antibiotics and Bravecto parasite control tap a $50 billion global market, less exposed to human drug pricing pressures. Winrevair, a recent cardio-pulmonary approval, signals diversification into rare diseases. For readers in the United States, these products align with domestic healthcare spending trends, supported by Medicare coverage.

Internationally, Merck navigates pricing reforms in Europe and volume growth in Asia, balancing U.S. market leadership. This geographic spread mitigates regulatory risks, ensuring you have exposure to resilient demand channels worldwide.

Industry Drivers Shaping Merck's Path Forward

Immuno-oncology remains the hottest segment, with checkpoint inhibitors like Keytruda setting sales records, but biosimilar competition looms post-patent. Vaccine demand surges post-pandemic, favoring Merck's established players amid public health pushes. You watch supply chain resilience, as global disruptions highlight needs for domestic manufacturing in critical drugs.

Aging populations drive chronic disease treatments, benefiting Merck's cardiology and diabetes pipeline candidates. Regulatory tailwinds from FDA fast tracks accelerate approvals, while pricing pressures from U.S. legislation test margins. For English-speaking markets worldwide, these drivers mean Merck's innovation edge translates to sustained relevance.

Sustainability in pharma, including greener manufacturing, gains traction, potentially unlocking efficiencies. Overall, these forces position Merck to capitalize if it navigates reimbursement hurdles adeptly.

Competitive Position: Strengths and Rivals

Merck holds a top spot in oncology, with Keytruda outpacing rivals like Bristol Myers' Opdivo in market share due to broader labels. Against Pfizer and Roche, Merck's pipeline depth in ADCs and bispecifics provides an edge. You appreciate the company's R&D spend, around 25% of sales, fueling 20+ Phase 3 trials.

In vaccines, Merck competes with GSK and Sanofi, but Gardasil's monopoly-like status endures. Animal health pits it against Zoetis, where innovation in biologics differentiates. Weaknesses include slower diabetes progress versus Eli Lilly's weight-loss stars.

Globally, Merck's scale enables cost advantages, but agile biotech challengers pressure legacy drugs. This positioning suits conservative investors seeking proven leaders over speculative plays.

Why Merck Matters for U.S. and Global Investors

In the United States, Merck's drugs fill PBM formularies and Medicare Part D, ensuring steady reimbursement amid IRA changes. You gain from dividend aristocrat status, with yields supporting retirement portfolios. Exposure to oncology megatrends aligns with healthcare's 18% GDP slice.

Across English-speaking markets like Canada, UK, and Australia, Merck's listings benefit from similar systems favoring innovative therapies. Tax-efficient structures and ADRs facilitate access. Economic resilience in these regions buffers pharma downturns.

Strategic U.S. manufacturing investments counter reshoring mandates, enhancing appeal. For you, Merck offers defensive growth in volatile markets, blending stability with upside.

Analyst Views: Consensus Leans Cautiously Optimistic

Reputable firms like JPMorgan and BofA maintain buy or overweight ratings on Merck stock, citing pipeline potential beyond Keytruda, though they flag patent risks. Average targets suggest modest upside from current levels, with emphasis on Winrevair launch success and vaccine momentum. Coverage highlights Merck's ROIC superiority versus peers, supporting capital returns.

Recent notes from Goldman Sachs note execution risks but praise M&A discipline. Overall, analysts project mid-single-digit EPS growth, tempered by biosimilar erosion. For you, this signals a hold-to-buy profile for dividend capture.

Risks and Open Questions You Should Watch

The Keytruda patent cliff post-2028 poses the biggest threat, with generics potentially halving sales rapidly. Pipeline failures, like past disappointments in Alzheimer's, could stall growth. Pricing reforms under potential policy shifts squeeze U.S. margins.

Regulatory delays or trial setbacks in oncology candidates create uncertainty. Competition intensifies from mRNA tech and cell therapies. Supply chain issues persist despite diversification.

What to watch next: Q2 earnings for pipeline updates, FDA decisions on new indications, and M&A activity. If Merck delivers label expansions, it could reassure you on post-Keytruda growth.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.